Organization · Venture Capital
4BIO Capital
4BIO Capital is a London-based venture capital firm specializing in early-stage investments in life sciences, particularly advanced therapies such as cell and gene therapy. Founded in 2014, it manages three funds focused on addressing high unmet medical needs.
Overview
What 4BIO Capital does
What 4BIO Capital is
4BIO Capital is a London-based venture capital firm specializing in early-stage investments in life sciences, particularly advanced therapies such as cell and gene therapy. Founded in 2014, it manages three funds focused on addressing high unmet medical needs.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2014
- Approximate age
- About 12 years
- Structured capabilities
- Funder
- Last reviewed
- April 24, 2026
Official channels
Find 4BIO Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
4BIO Capital as a funder
Investment thesis
4BIO Capital focuses exclusively on advanced therapies, investing in early-stage life sciences companies developing cell and gene therapies, RNA-based medicines, and microbiome treatments to address high unmet medical needs.
Focus narrative
The firm specializes in advanced therapies, particularly in cell and gene therapy, RNA-based therapy, targeted therapies, and microbiome innovations. 4BIO Capital seeks to invest in companies that are not only viable but also capable of addressing pressing medical and social challenges.
Value beyond capital
4BIO Capital adds value to its portfolio companies through deep scientific expertise and a robust network in the life sciences sector. The firm actively supports its companies in navigating the complexities of clinical development and market entry, leveraging its experience and connections to enhance growth and success.
Terms and economics
- Typical check
- $1,000,000–$75,000,000
- Sweet spot
- $10,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series A+
- Regions
- Global · Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 20
- Recorded notable exits
- Orchard Therapeutics
Portfolio context
Notable portfolio companies include: Trogenix: A cancer therapy company that raised £70 million in Series A financing for the clinical development of therapies targeting aggressive cancers. Actithera: Co-led an oversubscribed $75.5 million Series A financing to advance its therapeutic solutions. Araris Biotech: Recently announced its acquisition by Taiho Pharmaceutical for up to USD 1.14 billion, marking a significant exit for the firm.
Common questions
What to know about 4BIO Capital
Upseed classifies 4BIO Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 24, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.